Tag Archives: fda

FDA Approval of Keytruda will Help Some Mesothelioma Patients

FDA Approval of Keytruda

The FDA approval of Keytruda this month may help some patients in their battle against asbestos cancer.  Keytruda is the brand name for the immunotherapy drug pembrolizumab. The FDA first approved Keytruda as a first-line treatment for metastatic non-small cell lung cancer. That initial approval came in 2017. The new FDA approval of Keytruda is for treatment of specific kinds of malignant tumors. Eligible patients must have unresectable mesothelioma and no other treatment options.  How Keytruda Fights Mesothelioma Keytruda is an immune checkpoint inhibitor. It blocks a protein called PD-L1. Mesothelioma cells use PD-L1 to avoid immune system attack. Drugs like Keytruda unmask these hiding cells and make them more vulnerable to treatment.  But not all patients with mesothelioma will … Continue reading FDA Approval of Keytruda will Help Some Mesothelioma Patients »

Possible New Drug for Mesothelioma Gets First FDA Approval

new drug for mesothelioma

A possible new drug for mesothelioma has received FDA approval for the treatment of advanced epithelioid sarcoma.  Tazemetostat (Tazverik) is an oral medication made by a company called Epizyme. It is a brand new kind of drug that blocks a protein called EZH2. Tazemetostat is in testing for several different types of cancer, including malignant mesothelioma.  The recent FDA approval is an encouraging sign that it could one day be a new drug for mesothelioma.  In Search of a New Drug for Mesothelioma  Malignant mesothelioma is one of the most serious consequences of exposure to asbestos. Once asbestos fibers get into the lungs and other tissues, they never leave. Their presence sets up a cascade of cellular reactions that can … Continue reading Possible New Drug for Mesothelioma Gets First FDA Approval »

Tumor Treating Fields Win FDA Approval for Mesothelioma Treatment

Tumor Treating Fields

The FDA has approved an electricity-based mesothelioma treatment known as Tumor Treating Fields (NovoTTF-100L). The treatment is approved for use along with standard mesothelioma chemotherapy. It is the first new treatment for pleural mesothelioma since the approval of Alimta (pemetrexed) in 2004. Approval of NovoTTF-100L was based on the promising results of the STELLAR phase 2 mesothelioma clinical trial. Those results, released in April, were even better than expected. Electricity is the Basis of Tumor Treating Fields The Tumor Treating Fields approach was created by Jersey-based Novocure. It first found success in the treatment of the deadly brain cancer glioblastoma. The technology uses electrical fields to destabilize critical proteins responsible for cell division. When these proteins cannot do their job, … Continue reading Tumor Treating Fields Win FDA Approval for Mesothelioma Treatment »